You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NK Cell Exhaustion

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in New York (Pembrolizumab)

Terminated
Has Results
  • Melanoma
  • Pembrolizumab
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Oct 29, 2020

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Endothelial Function and Regenerative Cell Exhaustion

Not yet recruiting
  • Diabetes Mellitus, Type 2
    • Scarborough, Ontario, Canada
      Diagnostic Assessment Centre
    Oct 25, 2023

    AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

    Not yet recruiting
    • AML, Adult
    • Minimal Residual Disease
    • CD33/CLL1 dual CAR-NK cell
    • +5 more
    • Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Aug 4, 2023

    NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

    Not yet recruiting
    • NK Cell
    • +2 more
    • autologous NK cell
    • Hubei, Xiangyang, China
      EC of Xiangyang No.1 People's Hospital Hubei University of Medic
    Jun 19, 2023

    NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

    Not yet recruiting
    • NK-T-Cell Lymphoma, Extranodal
    • 4 cycles of ESA regimen with sandwiched radiotherapy
    • +2 more
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Sep 29, 2023

    Leukemia Trial (Donor Enriched Activated Natural Killer Cell Infusion)

    Withdrawn
    • Leukemia
    • Donor Enriched Activated Natural Killer Cell Infusion
    • (no location specified)
    Dec 20, 2022

    Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

    Recruiting
    • Acute Myeloid Leukemia
    • +3 more
    • CD123 targeted CAR-NK cells
    • Taiyuan, Shanxi, China
      Shanxi Bethune Hospital
    Aug 28, 2023

    T-Cell and NK-Cell Tumor Trial

    Not yet recruiting
    • T-Cell and NK-Cell Neoplasm
      • (no location specified)
      Sep 28, 2023

      Multiple Myeloma, Plasma Cell Leukemia Trial in Shanghai (Human BCMA targeted CAR-NK cells injection)

      Recruiting
      • Multiple Myeloma
      • Plasma Cell Leukemia
      • Human BCMA targeted CAR-NK cells injection
      • Shanghai, Shanghai, China
        Shanghai Changzheng Hospital
      Sep 13, 2023

      Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

      Not yet recruiting
      • Synovial Sarcoma
      • Fludarabine phosphate
      • +2 more
      • Houston, Texas
        MD Anderson Cancer Center
      Oct 9, 2023

      nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

      Recruiting
      • nk/T-cell Lymphoma
      • +2 more
      • XPO1 inhibitor
      • Beijing, Haidian, China
        ChinaPLAGH
      Apr 18, 2023

      Aggressive NK Cell Leukemia Trial in Hiroshima (PPMX-T003)

      Recruiting
      • Aggressive NK Cell Leukemia
      • Hiroshima, Japan
        Hiroshima University Hospital
      May 9, 2023

      Colorectal Cancer Trial (anesthetic method)

      Withdrawn
      • Colorectal Cancer
      • anesthetic method
      • (no location specified)
      Jul 11, 2023

      Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

      Recruiting
      • Immunotherapy
      • Multiple Myeloma
      • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
      • Zhengzhou, Henan, China
        Henan Cancer Hospital
      Dec 14, 2022

      NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

      Not yet recruiting
      • NK-T-Cell Lymphoma, Extranodal
      • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
      • (no location specified)
      Mar 7, 2023

      Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

      Not yet recruiting
      • Myeloma
      • Fludarabine phosphate
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Sep 27, 2023

      AML, Adult Recurrent, MDS Trial in Durham (DVX201)

      Recruiting
      • AML, Adult Recurrent
      • MDS
      • DVX201
      • Durham, North Carolina
        Duke University Hospital
      Feb 11, 2022

      AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

      Recruiting
      • AML, Adult
      • CLL1 CAR-NK cell injection
      • Hangzhou, Zhejiang, China
        Clinical research ethics committee of the first affiliated hospi
      Aug 30, 2023

      Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

      Recruiting
      • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
      • dualCAR-NK19/70 cell
      • Shanghai, Shanghai, China
        Shanghai Tongji Hospital, Tongji University School of Medicine
      Apr 24, 2023

      B-Cell Lymphoblastic Leukemia/Lymphoma Trial in Kunming (Anti-CD19 UCAR-NK cells)

      Recruiting
      • B-Cell Lymphoblastic Leukemia/Lymphoma
      • Anti-CD19 UCAR-NK cells
      • Kunming, Yunnan, China
        920th Hospital of Joint Logistics Support Force of People's Libe
      Dec 19, 2022

      Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

      Not yet recruiting
      • Extranodal NK/T-cell Lymphoma
      • Sugemalimab
      • +4 more
      • (no location specified)
      Jan 17, 2023

      Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)

      Recruiting
      • Acute Lymphoblastic Leukemia
      • +2 more
      • allogenic CD19-CAR-NK cells
      • Xuzhou, Jiangsu, China
        The Affiliated Hospital of Xuzhou Medical University
      Feb 11, 2023

      Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)

      Not yet recruiting
      • Peripheral T Cell Lymphoma
      • Zhengzhou, Henan, China
        Henan cancer hospital
      Jun 2, 2023

      B-cell Lymphoma, B-cell Leukemia Trial in Kunming (anti-CD19 UCAR-NK cells)

      Withdrawn
      • B-cell Lymphoma
      • B-cell Leukemia
      • anti-CD19 UCAR-NK cells
      • Kunming, Yunnan, China
        Kunming Hope of Health Hospital
      Nov 27, 2022